OMER - Omeros Corp Stock Price, Fair Value and News

3.03USD-0.06 (-1.94%)Market Closed

Market Summary

USD3.03-0.06

Market Closed

-1.94%

OMER Stock Price

View Fullscreen

OMER RSI Chart

OMER Valuation

Market Cap

179.0M

Price/Earnings (Trailing)

-1.52

Price/Sales (Trailing)

12.98

EV/EBITDA

-2.06

Price/Free Cashflow

2.41

OMER Price/Sales (Trailing)

OMER Profitability

EBT Margin

-1319.24%

Return on Equity

471.57%

Return on Assets

-31.15%

Free Cashflow Yield

41.5%

OMER Fundamentals

OMER Revenue

Revenue (TTM)

13.8M

Rev. Growth (Yr)

72.05%

Rev. Growth (Qtr)

-22.3%

OMER Earnings

Earnings (TTM)

-117.8M

Earnings Growth (Yr)

-107.04%

Earnings Growth (Qtr)

75.98%

Breaking Down OMER Revenue

Last 7 days

-9.9%

Last 30 days

-9.1%

Last 90 days

-10.7%

Trailing 12 Months

-49.4%

How does OMER drawdown profile look like?

OMER Financial Health

Current Ratio

4.09

Debt/Equity

-5.27

Debt/Cashflow

0.57

OMER Investor Care

Buy Backs (1Y)

7.78%

Diluted EPS (TTM)

0.65

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	7.4M	0	11.3M	13.8M
2022	2.5M	0	3.3M	4.1M
2021	71.3M	86.6M	44.2M	1.7M
2020	113.6M	100.3M	96.6M	73.8M
2019	50.1M	75.2M	100.4M	111.8M
2018	56.1M	47.3M	38.6M	29.9M
2017	46.5M	53.6M	64.0M	64.8M
2016	20.4M	27.2M	35.2M	41.4M
2015	827.0K	4.0M	7.0M	13.5M
2014	605.0K	510.0K	528.0K	539.0K
2013	5.6M	4.2M	3.0M	1.6M
2012	4.8M	5.2M	5.6M	6.0M
2011	3.0M	3.6M	4.4M	4.5M
2010	0	1.7M	1.9M	2.1M
2009	0	0	0	1.4M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Omeros Corp

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Nov 17, 2023	demopulos gregory a md	bought	25,200	1.68	15,000	chairman, ceo & president
Nov 15, 2023	demopulos peter a md	bought	15,300	1.53	10,000	-
Nov 14, 2023	demopulos gregory a md	acquired	36,000	1.44	25,000	chairman, ceo & president
Nov 13, 2023	demopulos gregory a md	acquired	48,375	1.29	37,500	chairman, ceo & president
Sep 12, 2023	bumol thomas f.	acquired	33,100	3.31	10,000	-
May 22, 2023	hanish arnold c	sold	-32,300	6.46	-5,000	-
May 22, 2023	hanish arnold c	acquired	26,500	5.3	5,000	-
May 22, 2023	cable thomas j.	sold	-32,650	6.53	-5,000	-
May 22, 2023	cable thomas j.	acquired	26,500	5.3	5,000	-
Sep 08, 2021	hanish arnold c	acquired	94,400	9.44	10,000	-

Which funds bought or sold OMER recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Apr 23, 2024	AMALGAMATED BANK	reduced	-69.19	-15,000	7,000	-%
Apr 23, 2024	FIFTH THIRD BANCORP	unchanged	-	180	3,450	-%
Apr 22, 2024	RAYMOND JAMES & ASSOCIATES	sold off	-100	-35,725	-	-%
Apr 22, 2024	MetLife Investment Management, LLC	unchanged	-	11,293	105,510	-%
Apr 17, 2024	Private Ocean, LLC	sold off	-100	-4,088	-	-%
Apr 10, 2024	Apella Capital, LLC	unchanged	-	5,715	49,008	-%
Mar 27, 2024	NOMURA HOLDINGS INC	reduced	-13.99	-47,926	1,252,880	-%
Mar 22, 2024	PNC FINANCIAL SERVICES GROUP, INC.	new	-	43.00	43.00	-%
Mar 15, 2024	B. Riley Wealth Advisors, Inc.	reduced	-6.5	2,113	47,023	-%
Mar 11, 2024	VANGUARD GROUP INC	added	0.83	1,185,300	10,362,400	-%

Are Funds Buying or Selling OMER?

Are funds buying OMER calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own OMER

No. of Funds

Unveiling Omeros Corp's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Mar 27, 2024	ingalls & snyder llc	7.0%	4,431,188	SC 13G/A
Feb 14, 2024	demopulos gregory a md	8.80%	5,704,061	SC 13G/A
Feb 13, 2024	vanguard group inc	5.04%	3,168,936	SC 13G
Jan 29, 2024	blackrock inc.	6.8%	4,279,836	SC 13G
Feb 17, 2023	ingalls & snyder llc	6.6%	4,131,793	SC 13G/A
Feb 14, 2023	demopulos gregory a md	8.37%	5,551,980	SC 13G/A
Feb 09, 2023	vanguard group inc	4.50%	2,820,445	SC 13G/A
Jul 08, 2022	blackrock inc.	2.0%	1,225,787	SC 13G
Feb 14, 2022	demopulos gregory a md	8.07%	5,314,624	SC 13G/A
Feb 14, 2022	cormorant asset management, lp	0%	0	SC 13G/A

Recent SEC filings of Omeros Corp

View All Filings

Date Filed	Form Type	Document
Apr 01, 2024	8-K	Current Report
Apr 01, 2024	10-K	Annual Report
Mar 27, 2024	SC 13G/A	Major Ownership Report
Feb 14, 2024	SC 13G/A	Major Ownership Report
Feb 13, 2024	SC 13G	Major Ownership Report
Feb 07, 2024	8-K	Current Report
Jan 29, 2024	SC 13G	Major Ownership Report

Peers (Alternatives to Omeros Corp)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	41.2B	6.8B	2.33%	-21.90%	-8.74	6.02	-64.45%	-156.37%
HILS	22.4B	152.6K	-0.77%	465779.94%	-2.4K	146.8K	-	-9.98%
ALNY	18.4B	1.8B	-0.30%	-28.67%	-41.79	10.06	76.23%	61.08%
BMRN	17.4B	2.4B	8.14%	-4.26%	103.61	7.18	15.42%	18.43%
INCY	11.6B	3.7B	-9.39%	-31.39%	19.4	3.14	8.87%	75.42%
MID-CAP
APLS	5.9B	396.6M	-12.04%	-45.12%	-11.11	14.81	425.83%	18.94%
BBIO	4.5B	-	-13.93%	67.39%	-6.85	60.35	54.84%	-34.79%
AXSM	3.5B	270.6M	-9.40%	-0.33%	-14.47	12.79	440.80%	-27.84%
ARWR	2.9B	240.7M	-12.61%	-20.79%	-9.93	12.18	-1.03%	-92.09%
ACAD	2.8B	726.4M	-6.74%	-16.88%	-45.01	3.8	40.45%	71.62%
SMALL-CAP
CPRX	1.7B	398.2M	-6.36%	-10.84%	24.31	4.36	85.90%	-14.05%
NVAX	587.8M	983.7M	-10.64%	-48.02%	-1.08	0.6	-50.36%	17.16%
CRBP	396.0M	881.7K	8.01%	271.09%	-8.88	466.16	-77.61%	-5.33%
INO	242.4M	4.9M	-10.76%	0.48%	-1.79	49.8	-54.97%	51.71%
IBIO	6.7M	2.1M	76.15%	62.71%	-0.25	2.14	-13.45%	66.37%

Omeros Corp News

Latest updates

Omeros Corp Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

Income Statement (Quarterly)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q1	2022Q4	2022Q3	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4	2018Q3	2018Q2
Revenue	-22.3%	3,429,000	4,413,000	3,963,000	1,993,000	906,000	493,000	9,936,333	19,379,667	28,823,000	21,061,000	10,632,000	26,114,000	13,530,000	23,537,000	33,417,000	29,856,000	26,753,000	21,779,000	22,017,000	4,608,000	1,655,000
Costs and Expenses	-17.4%	39,765,000	48,153,000	35,713,000	40,138,500	50,766,000	35,046,000	42,889,000	39,828,000	45,610,000	45,290,000	44,448,000	51,542,000	41,210,000	47,214,000	57,121,000	40,957,000	36,091,000	41,018,000	40,491,000	40,050,000	32,272,000
Operating Expenses	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	41,018,000	40,491,000	40,050,000	32,272,000
S&GA Expenses	-33.8%	10,875,000	16,422,000	11,103,000	13,589,000	12,198,000	10,959,000	12,562,000	14,010,000	15,484,000	12,786,000	-5,486,000	19,825,000	16,931,000	18,036,000	-8,779,000	16,933,000	16,928,000	14,632,000	14,888,000	13,152,000	12,744,000
R&D Expenses	-9.0%	28,890,000	31,731,000	24,610,000	26,549,500	38,568,000	24,087,000	30,327,000	25,818,000	30,126,000	32,504,000	23,253,000	31,316,000	24,132,000	28,911,000	37,215,500	23,746,000	19,108,000	26,255,000	25,446,000	26,862,000	19,412,000
EBITDA Margin	17.8%	-10.89	-13.25	-20.27	-38.98	-9.39	-5.09	-3.50	-2.70	-2.73	-3.30	-	-	-	-	-	-	-	-	-	-	-
Interest Expenses	-10.8%	7,063,000	7,916,000	7,933,000	7,902,500	4,932,000	4,941,000	4,951,000	4,911,000	4,910,000	4,897,000	7,988,000	6,882,000	5,978,000	5,903,000	5,811,500	5,715,000	5,530,000	5,600,000	5,148,500	4,602,000	3,676,000
Income Taxes	-	-	-	-	-	-	-	-	-	-	-	-15,402,000	-7,854,000	-	-	-	-	-	-	-	-	-
Earnings Before Taxes	-	-	-	-	-	-	-	-105,160,000	-22,703,000	-	-	-87,747,000	-46,317,000	-	-	-111,881,000	-16,463,000	-	-	-	-	-
EBT Margin	18.3%	-13.19	-16.14	-23.74	-44.81	-10.20	-5.54	-3.80	-2.97	-3.03	-3.68	-	-	-	-	-	-	-	-	-	-	-
Net Income	76.0%	-9,068,000	-37,750,000	-33,701,000	128,733,000	-17,456,000	-33,011,000	280,621,000	-22,703,000	-28,593,000	-35,090,000	-37,273,000	-38,463,000	-33,294,000	-29,031,000	-29,225,000	-16,463,000	-14,453,000	-24,345,000	-23,534,000	-39,472,000	-33,696,000
Net Income Margin	-581.6%	-8.54	1.77	6.09	11.67	7.76	4.15	2.82	-1.37	-1.61	-2.02	-	-	-	-	-	-	-	-	-	-	-
Free Cashflow	-6.9%	-34,943,000	-32,680,000	174,526,000	-25,395,000	-26,436,000	-15,267,000	-18,289,000	-23,764,000	-27,680,000	-40,266,000	-	-	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Assets	-23.3%	378	493	527	560	591	458	346	369	419	123	145	161	181	227	71.00	118	137	91.00	90.00	101	96.00
Current Assets	-38.0%	218	351	389	417	443	289	193	210	248	91.00	112	132	151	196	39.00	86.00	104	64.00	66.00	77.00	90.00
Cash Equivalents	-76.8%	7.00	31.00	7.00	4.00	11.00	146	14.00	9.00	101	7.00	13.00	9.00	11.00	21.00	2.00	7.00	3.00	9.00	4.00	4.00	6.00
Inventory	-	-	-	-	-	-	-	-	-	-	1.00	1.00	1.00	1.00	2.00	2.00	1.00	1.00	1.00	1.00	1.00	0.00
Net PPE	13.6%	2.00	2.00	-	-	1.00	-	-	-	-	-	-	-	-	3.00	3.00	3.00	4.00	4.00	4.00	4.00	4.00
Current Liabilities	-63.8%	53.00	147	144	139	136	40.00	39.00	35.00	52.00	43.00	48.00	43.00	37.00	48.00	38.00	58.00	55.00	47.00	41.00	45.00	37.00
LT Debt, Current	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	3.00	1.00
Shareholder's Equity	-Infinity%	-24.98	-	21.00	55.00	86.00	-	-	-	24.00	-	-	-	-120	-	-	-	-	-	-	-	-
Retained Earnings	-1.2%	-753	-744	-706	-669	-635	-764	-746	-716	-683	-963	-941	-912	-872	-835	-796	-763	-734	-705	-688	-674	-650
Additional Paid-In Capital	-0.3%	728	730	727	724	721	718	714	711	706	700	694	690	751	747	635	631	625	565	558	553	549
Shares Outstanding	-2.8%	61.00	63.00	63.00	63.00	63.00	63.00	63.00	63.00	63.00	63.00	62.00	62.00	-	-	-	-	-	-	-	-	-
Float	-	-	-	-	-	-	-	166	-	-	-	887	-	-	-	762	-	-	-	729	-	-

Cashflow (Last 12 Months)

(In Thousands)

Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Cashflow From Operations	-6.7%	-34,825	-32,647	-32,341	174,539	-25,382	-26,439	-19,469	-15,193	-18,215	-23,661	-27,592	-40,254	-18,407	-34,941	-37,597	-9,141	-23,014	-7,522	-16,589	-12,948	-24,657
Share Based Compensation	-16.8%	2,691	3,235	2,771	2,953	3,264	3,844	3,072	3,892	5,548	5,694	3,117	3,271	3,803	3,824	3,822	3,476	3,317	3,496	3,598	3,374	2,818
Cashflow From Investing	103.3%	116,243	57,167	35,375	-181,331	-108,491	32,999	24,741	-76,813	112,418	17,896	30,411	32,985	7,996	-118,397	32,594	10,776	-39,239	9,339	15,212	11,287	-2,361
Cashflow From Financing	-21629.4%	-104,953	-483	-260	-388	-651	124,837	-99.00	161	-810	478	855	5,796	-163	172,449	-151	2,399	56,476	3,058	1,309	-146	30,092

OMER Income Statement

2023-12-31

Consolidated Statements of Operations and Comprehensive Income (Loss) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Costs and expenses:
Research and development	$ 114,870	$ 112,721	$ 118,775
Selling, general and administrative	49,660	50,668	54,842
Total costs and expenses	164,530	163,389	173,617
Loss from operations	(164,530)	(163,389)	(173,617)
Interest expense	(30,844)	(22,702)	(19,669)
Interest and other income	16,342	4,062	1,740
Gain on early extinguishment of convertible senior notes	4,112	0	0
Net loss from continuing operations	(174,920)	(182,029)	(191,546)
Net income from discontinued operations, net of tax	57,107	229,446	385,781
Net income (loss)	$ (117,813)	$ 47,417	$ 194,235
Basic and diluted net income (loss) per share:
Net loss from continuing operations (in dollars per share)	$ (2.79)	$ (2.9)	$ (3.07)
Net income from discontinued operations (in dollars per share)	0.91	3.66	6.19
Net income (loss) (in dollars per share)	$ (1.88)	$ 0.76	$ 3.12
Weighted-average shares used to compute basic and diluted net income (loss) per share (in shares)	62,739,227	62,737,091	62,344,100

OMER Balance Sheet

2023-12-31

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 7,105	$ 11,009
Short-term investments	164,743	183,909
OMIDRIA contract royalty asset, short-term	29,373	28,797
Receivables	8,096	213,221
Prepaid expense and other assets	8,581	6,300
Total current assets	217,898	443,236
OMIDRIA contract royalty asset	138,736	123,425
Right of use assets	18,631	21,762
Property and equipment, net	1,950	1,492
Restricted investments	1,054	1,054
Total assets	378,269	590,969
Current liabilities:
Accounts payable	7,712	5,989
Accrued expenses	31,868	30,551
Current portion of convertible senior notes, net	0	94,381
Current portion of OMIDRIA royalty obligation	8,576	1,152
Current portion of lease liabilities	5,160	4,310
Total current liabilities	53,316	136,383
Convertible senior notes, net	213,155	220,906
OMIDRIA royalty obligation	116,550	125,126
Lease liabilities, non-current	18,143	22,426
Other accrued liabilities - noncurrent	2,088	444
Commitments and contingencies (Note 10)
Shareholders’ equity (deficit):
Preferred stock, par value $0.01 per share, 20,000,000 shares authorized; none issued and outstanding at December 31, 2023 and December 31, 2022	0	0
Common stock, par value $0.01 per share, 150,000,000 shares authorized at December 31, 2023 and December 31, 2022; 61,128,597 and 62,828,765 shares issued and outstanding at December 31, 2023 and December 31, 2022, respectively.	611	628
Additional paid-in capital	727,936	720,773
Accumulated deficit	(753,530)	(635,717)
Total shareholders’ equity (deficit)	(24,983)	85,684
Total liabilities and shareholders’ equity (deficit)	$ 378,269	$ 590,969

About Omeros Corp

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting inflammation, complement-mediated diseases, cancers, and addictive and compulsive disorders. The company's clinical programs include Narsoplimab (OMS721/MASP-2) that has completed pivotal studies for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (HSCT-TMA); that is in Phase III clinical trial for immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19. It also develops OMS1029 that is in phase I clinical trials for long-acting second-generation antibody targeting lectin pathway disorders; OMS906 that is in phase Ib clinical trials for Paroxysmal nocturnal hemoglobinuria, complement 3 glomerulopathy, and other alternative pathway disorders; OMS527 that is in phase I clinical trials for addictions and compulsive disorders, and movement disorders; and OMS405 that is in phase II clinical trials for opioid and nicotine addiction. In addition, the company develops MASP-2-small-molecule inhibitors for the treatment of aHUS, HSCT-TMA, and age-related macular degeneration; GPR174 inhibitors and chimeric antigen receptor T-Cell and adoptive T-Cell therapies for various cancers; and G protein-coupled receptors for treating immunologic, immuno-oncologic, metabolic, CNS, cardiovascular, musculoskeletal, and other disorders. Omeros Corporation was incorporated in 1994 and is headquartered in Seattle, Washington.

CEO	Dr. Gregory A. Demopulos M.D.
WEBSITE	omeros.com
INDUSTRY	Biotechnology
EMPLOYEES	196

Omeros Corp Frequently Asked Questions

What is the ticker symbol for Omeros Corp? What does OMER stand for in stocks?

OMER is the stock ticker symbol of Omeros Corp. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Omeros Corp (OMER)?

As of Tue Apr 23 2024, market cap of Omeros Corp is 179.04 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of OMER stock?

You can check OMER's fair value in chart for subscribers.

What is the fair value of OMER stock?

You can check OMER's fair value in chart for subscribers. The fair value of Omeros Corp is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Omeros Corp is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for OMER so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Omeros Corp a good stock to buy?

The fair value guage provides a quick view whether OMER is over valued or under valued. Whether Omeros Corp is cheap or expensive depends on the assumptions which impact Omeros Corp's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for OMER.

What is Omeros Corp's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Tue Apr 23 2024, OMER's PE ratio (Price to Earnings) is -1.52 and Price to Sales (PS) ratio is 12.98. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. OMER PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Omeros Corp's stock?

In the past 10 years, Omeros Corp has provided -0.123 (multiply by 100 for percentage) rate of return.